萘莫司他——血液净化抗凝新选择  

Nafamostat:A New Anticoagulation Choice for Blood Purification

作　　者：李双双 赵德鹏 丁征 LI Shuang-shuang;ZHAO De-peng;DING Zheng(Anticoagulation Pharmacist SpelialtyCollaborative Group,Branch ofCardiovascular Pharmacy,ChineseSociety of Cardiothoracic and VascularAnsthesiology;Department of Phammacy,The Seoond Aflted Hospital of ShandongUniversity of Traditional Chinese Medidine,Jinan 250001,China;Department ofPharmacy,Central Hospital of DalianUniversity of Technology,Dallian 116000,China;Department of Pharmacy,Fuwai Hospital,Chinese Academy of Medical Sdiences,Beiling 100037,China)

机构地区：[1]中国心胸血管麻醉学会心血管药学分会抗凝药师专科协作组 [2]山东中医药大学第二附属医院药学部,济南250001 [3]大连理工大学附属中心医院药学部,大连116000 [4]中国医学科学院阜外医院药剂科,北京100037

出　　处：《中国合理用药探索》2025年第2期30-34,共5页Chinese Journal of Rational Drug Use

基　　金：2022年度北京市慢性病防治与健康教育科研项目(BJMB0012022028007)。

摘　　要：甲磺酸萘莫司他(NM)因其良好的生物学特性在延长滤过器寿命、减少出血风险等方面具有较为明显的优势,相比局部枸橼酸抗凝操作也更加简便。NM用于体外循环抗凝已有30多年的历史,并显示出良好的体外抗凝性能,特别是在高危出血风险患者中优势更加明显。本文介绍了NM的作用机制、使用方法、在不同出血风险和高凝状态中的应用,并对比了NM、普通肝素、低分子肝素、局部枸橼酸抗凝4种抗凝方式的特点,有助于临床合理使用抗凝药物。Nafamostat mesylate(NM)shows obvious advantages in prolonging filter lifespan and reducing bleeding risks due to its favorable biological properties,and it is also easier to operate than regional citrate anticoagulation.NM has been used for anticoagulation during extracorporeal circulation for more than 30 years and has shown excellent extracorporeal anticoagulation performance,especially in patients at high risk of bleeding.This article introduces the mechanism of action,application methods,and the use of NM in different bleeding risks and hypercoagulable states,and provides a comparison of the characteristics of four anticoagulation methods(NM,unfractionated heparin,low-molecular-weight heparin and regional citrate anticoagulation),contributing to the rational clinical use of anticoagulants.

关 键 词：萘莫司他 抗凝 血液净化 枸橼酸 局部抗凝 

分 类 号：R972[医药卫生—药品]